Visual Universitätsmedizin Mainz


The skin cancer center of the UCT provides multi- and interdisciplinary service for patients with all types of primary and metastatic cutaneous malignancies. This includes surgical procedures, topical and systemic therapies as well as palliative, psychooncological, follow-up and preventive care of skin cancer patients. In 2014, 278 new patients with primary melanoma, 437 patients with epithelial skin cancer, 43 cutaneous lymphomas and other types of skin cancer were seen at the UCT. In 2014, 1,340 patients were operated for skin cancer, 99 sentinel node biopsies and 996 histological examinations of skin cancers were performed. More than 400 patients were discussed at the interdisciplinary skin cancer conference in 2014, and more than 1,000 patients were followed up as outpatients by the team.

Clinical Research

Several first-in-man trials are being conducted within the translational Melanoma / Skin cancer program. We substantially contribute to the IVAC (Individualized Vaccines Against Cancer) MUTANOM phase I clinical trial in melanoma, as well as in RNA-based vaccination trials carried out together with Biontech AG (MERIT-Trials). Within the clinical research program, 52 patients were treated in interventional clinical trials in 2014, and recent publications document active contribution to international clinical trials (Van Allen E.M. Science 2015; Ribas A. Lancet Oncology 2015; Migden M.R. Lancet Oncology 2015). Moreover, S. Grabbe and C. Loquai are both members of the steering committee of the DeCOG (German cooperative cutaneous oncology group), the leading German skin cancer research organization.

Translational Melanoma Projects

Basic and translational research, with a focus on immunotherapy, is the prime scientific interest. In 2012, a DFG-funded collaborative research consortium was established focusing on the utilization of multi-functionalized nanoparticles and polymers for melanoma immunotherapy (SFB1066). In addition, DKTK- and FZI-funded projects are actively investigating aspects of immunomodulation in melanoma.

Most significant publications

  • Migden M.R., A. Guminski, R. Gutzmer, L. Dirix, K.D. Lewis, P. Combemale, R.M. Herd, R. Kudchadkar, U. Trefzer, S. Gogov, C. Pallaud, T. Yi, M. Mone, M. Kaatz, C. Loquai, A.J. Stratigos, H.J. Schulze, R. Plummer, A.L. Chang, F. Cornélis, J.T. Lear, D. Sellami, R. Dummer. 2015. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 16(6):716-28.
  • Ribas A., I. Puzanov, R. Dummer, D. Schadendorf, O. Hamid, C. Robert, F.S. Hodi, J. Schachter, A.C. Pavlick, K.D. Lewis, L.D. Cranmer, C.U. Blank, S.J. O'Day, P.A. Ascierto, A.K. Salama, K.A. Margolin, C. Loquai, T.K. Eigentler, T.C. Gangadhar, M.S. Carlino, S.S. Agarwala, S.J. Moschos, J.A. Sosman, S.M. Goldinger, R. Shapira-Frommer, R. Gonzalez, J.M. Kirkwood, J.D. Wolchok, A. Eggermont, X.N. Li, W. Zhou, A.M. Zernhelt, J. Lis, S. Ebbinghaus, S.P. Kang, A. Daud. 2015. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16(8):908-18.
  • Van Allen E.M., D. Miao, B. Schilling, S.A. Shukla, C. Blank, L. Zimmer, A. Sucker, U. Hillen, M.H. Foppen, S.M. Goldinger, J. Utikal, J.C. Hassel, B. Weide, K.C. Kaehler, C. Loquai, P. Mohr, R. Gutzmer, R. Dummer, S. Gabriel, C.J. Wu, D. Schadendorf, L.A. Garraway. 2015. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 350(6257):207-11.